Provider Briefing: Amikacin Supply Remains Constrained in 2026

The Amikacin injection shortage is not a new development, but it remains a persistent challenge for infectious disease specialists, intensivists, and any provider managing serious gram-negative infections. As of early 2026, key presentations of Amikacin Sulfate injection continue to be listed on the ASHP Drug Shortage Database, and the outlook for full supply recovery remains uncertain.

This article provides a clinical and logistical overview for prescribers navigating the Amikacin supply gap — including shortage timeline, prescribing considerations, cost implications, and practical tools for patient access.

Shortage Timeline and Current Status

Amikacin injection (250 mg/mL) has experienced intermittent shortages since at least 2015, with the most significant supply disruptions occurring in recent years:

• Hikma (West-Ward Pharmaceuticals) — 2 mL (500 mg) and 4 mL (1,000 mg) vials have been on long-term back order with no estimated release date
• Other manufacturers (Fresenius Kabi, others) have experienced periods of limited availability
• The FDA has been monitoring the situation and working with manufacturers, though no new market entrants have been announced

The shortage is primarily driven by the economics of generic sterile injectable manufacturing: limited producers, complex production requirements, thin margins, and vulnerability to API supply chain disruptions.

Prescribing Implications

The constrained supply of Amikacin has several clinical implications:

Antimicrobial Stewardship Considerations

• Reserve Amikacin for infections where culture and sensitivity data demonstrate resistance to Gentamicin and Tobramycin
• Avoid empiric Amikacin use when alternative aminoglycosides are likely to be effective
• Coordinate with antimicrobial stewardship teams to optimize allocation of available supply

Therapeutic Drug Monitoring

When Amikacin is available and prescribed, ensure rigorous therapeutic drug monitoring (TDM):

• Peak levels: 20–35 mcg/mL (conventional dosing) or 56–64 mcg/mL (extended-interval dosing)
• Trough levels: <5 mcg/mL (conventional) or <1 mcg/mL (extended-interval)
• Monitor renal function (BUN, serum creatinine) at baseline and every 2–3 days
• Audiometric monitoring for treatment courses exceeding 7–10 days

Patient Communication

Patients prescribed Amikacin should be informed about the shortage proactively. Setting expectations about potential sourcing delays and discussing contingency plans helps prevent treatment interruptions. Direct patients to resources like the patient-facing shortage update for additional context.

Current Availability Picture

Supply is inconsistent and varies by distributor, region, and vial size. Key points:

• The 4 mL vial (1,000 mg) has been more consistently back-ordered than the 2 mL vial
• Some distributors may have intermittent supply from secondary sources
• 503B outsourcing facilities may be able to compound Amikacin injection during declared shortages under FDA enforcement discretion
• Hospital systems with group purchasing organization (GPO) contracts may have better access through allocation programs

For real-time availability data across suppliers, providers can use Medfinder for Providers to search current stock.

Cost and Access Considerations

Generic Amikacin injection remains relatively affordable when available:

• Wholesale acquisition cost (WAC): Variable during shortages, but typically $5–$15 per vial (500 mg/2 mL) at baseline
• Cash price for patients (outpatient): $53–$161 for 10 vials without insurance; as low as $41 with discount programs
• Insurance: Generally covered as a generic injectable. Outpatient IV therapy may require prior authorization for home infusion services

The branded product Arikayce (Amikacin liposome inhalation suspension by Insmed) is indicated only for MAC lung disease and carries a substantially higher price point — it should not be considered interchangeable with injectable Amikacin for general bacterial infections.

Alternative Agents

When Amikacin is unavailable, alternative aminoglycosides and other agents should be selected based on culture and sensitivity data:

• Gentamicin — first-line aminoglycoside alternative with broader availability; check susceptibility patterns as cross-resistance is not universal
• Tobramycin — preferred for Pseudomonas aeruginosa; available as both injectable and inhaled formulations
• Plazomicin (Zemdri) — next-generation aminoglycoside with activity against many aminoglycoside-resistant organisms; FDA-approved for cUTI/pyelonephritis
• Carbapenems, polymyxins, or combination beta-lactam/beta-lactamase inhibitors — depending on the resistance profile

For detailed alternative considerations, see our clinical guide on Amikacin alternatives.

Tools and Resources for Providers

• Medfinder for Providers — real-time medication availability search across pharmacies and suppliers
• ASHP Drug Shortage Database — official shortage tracking with manufacturer updates
• FDA Drug Shortage page — federal oversight and mitigation information
• Institutional pharmacy contacts — GPO allocation requests and 503B compounding coordination

Looking Ahead

The structural factors driving Amikacin shortages — limited manufacturers, complex sterile production, and thin economic margins — are unlikely to resolve quickly. Providers should:

• Incorporate aminoglycoside availability into empiric therapy decision-making
• Maintain institutional protocols for aminoglycoside substitution during shortages
• Advocate for policy solutions that incentivize generic injectable antibiotic manufacturing
• Use tools like Medfinder to stay current on real-time supply

Final Thoughts

The Amikacin shortage is a systemic issue that requires both immediate clinical workarounds and long-term policy attention. By staying informed, leveraging real-time availability tools, and maintaining flexibility in treatment protocols, providers can continue to deliver effective care despite supply constraints.

For additional provider resources, see our guide on helping patients find Amikacin, helping patients save money on Amikacin, and the patient-facing article on Amikacin drug interactions.